The invention relates to a solid water-dispersible pharmaceutical compositionfor use in the treatment of a disease, said treatment comprising dispersing the pharmaceutical composition into an aqueous liquid to produce an enterally administrable liquid containing at least 0.5 grams of the pharmaceutical composition and at least 0.3 g/l of edaravone, followed by enterally administering the enterally administrable liquid to a human patient in an amount providing a dose of 30-300 mg edaravone, said pharmaceutical composition comprising: ⋅ 2-50 wt.% of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone)； and ⋅ 3-50 wt.% of water soluble alkalizing agent. This solid edaravone containing composition can easily be dispersed in aqueous liquid to prepare an aqueous edaravone solution that can be ingested by a patient. The solid composition of the present invention offers the advantage that edaravone dissolves very rapidly when the composition is introduced into water and that the enterally administrable liquid so obtained has high oral bioavailability.
